UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression

Immunity (Cambridge, Mass.), 2017-08, Vol.47 (2), p.284-297.e5

2017

Volltextzugriff (PDF)

Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy

Scientific reports, 2022-06, Vol.12 (1), p.9559-9559, Article 9559

2022

Volltextzugriff (PDF)

A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)

Translational oncology, 2019-06, Vol.12 (6), p.828-835

2019

Volltextzugriff (PDF)

Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study

Cancer Immunology, Immunotherapy, 2020-09, Vol.69 (9), p.1713-1724

2020

Volltextzugriff (PDF)

Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese population-based analysis

Frontiers in immunology, 2022-12, Vol.13, p.1083840-1083840

2022

Volltextzugriff (PDF)

An immune risk score predicts progression-free survival of melanoma patients in South China receiving anti-PD-1 inhibitor therapy-a retrospective cohort study examining 66 circulating immune cell subsets

Frontiers in immunology, 2022-12, Vol.13, p.1012673-1012673

2022

Volltextzugriff (PDF)

A pilot study of lymphodepletion intensity for peripheral blood mononuclear cell-derived neoantigen-specific CD8 + T cell therapy in patients with advanced solid tumors

Nature communications, 2023-06, Vol.14 (1), p.3447-3447, Article 3447

2023

Volltextzugriff (PDF)

Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study

Frontiers in immunology, 2022-10, Vol.13, p.882471

2022

Volltextzugriff (PDF)

Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling

Frontiers in oncology, 2021-06, Vol.11, p.698888-698888

2021

Volltextzugriff (PDF)

Time-varying pattern of recurrence risk for localized melanoma in China

World journal of surgical oncology, 2020-01, Vol.18 (1), p.6-6, Article 6

2020

Volltextzugriff (PDF)

Whole‐exome sequencing in clear cell sarcoma of soft tissue uncovers novel prognostic categorization and drug targets

Clinical and translational medicine, 2021-12, Vol.11 (12), p.e640-n/a

2021

Volltextzugriff (PDF)

Real-world efficacy and safety data of anti-PD-1 plus anti-CTLA-4 combination therapy in Chinese patients with advanced melanoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e21530-e21530

2023

Volltextzugriff (PDF)

Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response

Cell research, 2022-06, Vol.32 (6), p.530-542

2022

Volltextzugriff (PDF)

Intrathecal anti-PD-1 treatment in metastatic melanoma patients with leptomeningeal disease (LMD): real-world data and evidence

Journal of neuro-oncology, 2024-10

2024

Volltextzugriff (PDF)

Intrathecal anti-PD-1 treatment in patients with metastatic melanoma (MM) with leptomeningeal disease (LMD): Real-world data and evidence

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e21516-e21516

2023

Volltextzugriff (PDF)

Clinical features and response to systemic therapy in NRAS-mutant Chinese melanoma patients

Journal of cancer research and clinical oncology, 2023-02, Vol.149 (2), p.701-708

2023

Volltextzugriff (PDF)

Chimeric antigen receptor‐modified T‐cell therapy for platelet‐derived growth factor receptor α‐positive rhabdomyosarcoma

Cancer, 2020-05, Vol.126 (S9), p.2093-2100

2020

Volltextzugriff (PDF)

Adjuvant PD-1 inhibitor versus high-dose interferon α-2b for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e21516-e21516

2021

Volltextzugriff (PDF)

The experience of immune checkpoint inhibitors in Chinese patients with metastatic melanoma: a retrospective case series

Cancer Immunology, Immunotherapy, 2017-09, Vol.66 (9), p.1153-1162

2017

Volltextzugriff (PDF)

A pilot study of lymphodepletion intensity for PBMC-derived, neoantigen-specific CD8+ T cells (Neo-Ts) therapy in patients with advanced solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2545-2545

2023

Volltextzugriff (PDF)

Adjuvant PD‐1 inhibitor versus high‐dose interferon α‐2b for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis

Dermatologic therapy, 2021-09, Vol.34 (5), p.e15067-n/a

2021

Volltextzugriff (PDF)

Phase I clinical trial to assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of NY-ESO-1–specific TCR T-cells (TAEST16001) in HLA-A02:01 patients with advanced soft tissue sarcoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.11502-11502

2022

Volltextzugriff (PDF)

Second-line (2L) pembrolizumab (pembro) in Chinese patients (pts) with advanced melanoma: Three-year follow up (FU) of the phase 1 KEYNOTE-151 study

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e21511-e21511

2021

Volltextzugriff (PDF)

Mutation landscape of Chinese melanoma patients

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9563-9563

2019

Volltextzugriff (PDF)

Phase I study results of APG-115, a MDM2-p53 antagonist in Chinese patients with advanced liposarcoma and other solid tumors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.11542-11542

2020

Volltextzugriff (PDF)

1 – 25 von 66

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(56)

Publikationsform

Sprache

Englisch
(64)
Chinesisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression

Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy

A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)

Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study

Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese population-based analysis

An immune risk score predicts progression-free survival of melanoma patients in South China receiving anti-PD-1 inhibitor therapy-a retrospective cohort study examining 66 circulating immune cell subsets

A pilot study of lymphodepletion intensity for peripheral blood mononuclear cell-derived neoantigen-specific CD8 + T cell therapy in patients with advanced solid tumors

Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study

Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling

Time-varying pattern of recurrence risk for localized melanoma in China

Whole‐exome sequencing in clear cell sarcoma of soft tissue uncovers novel prognostic categorization and drug targets

Real-world efficacy and safety data of anti-PD-1 plus anti-CTLA-4 combination therapy in Chinese patients with advanced melanoma

Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response

Intrathecal anti-PD-1 treatment in metastatic melanoma patients with leptomeningeal disease (LMD): real-world data and evidence

Intrathecal anti-PD-1 treatment in patients with metastatic melanoma (MM) with leptomeningeal disease (LMD): Real-world data and evidence

Clinical features and response to systemic therapy in NRAS-mutant Chinese melanoma patients

Chimeric antigen receptor‐modified T‐cell therapy for platelet‐derived growth factor receptor α‐positive rhabdomyosarcoma

Adjuvant PD-1 inhibitor versus high-dose interferon α-2b for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis

The experience of immune checkpoint inhibitors in Chinese patients with metastatic melanoma: a retrospective case series

A pilot study of lymphodepletion intensity for PBMC-derived, neoantigen-specific CD8+ T cells (Neo-Ts) therapy in patients with advanced solid tumors

Adjuvant PD‐1 inhibitor versus high‐dose interferon α‐2b for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis

Phase I clinical trial to assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of NY-ESO-1–specific TCR T-cells (TAEST16001) in HLA-A02:01 patients with advanced soft tissue sarcoma

Second-line (2L) pembrolizumab (pembro) in Chinese patients (pts) with advanced melanoma: Three-year follow up (FU) of the phase 1 KEYNOTE-151 study

Mutation landscape of Chinese melanoma patients

Phase I study results of APG-115, a MDM2-p53 antagonist in Chinese patients with advanced liposarcoma and other solid tumors

Suchergebnisse filtern